Applied DNA Stock Surges On Launch Plans For Linea 2.0 COVID-19 Assay For Omicron Variant

Applied DNA Sciences Inc (NASDAQ:APDN) plans to introduce its Linea 2.0 COVID-19 Assay for the SARS-CoV-2 E and N genes after submitting its validation data to the New York State Department of Health (NYSDOH) in the next few days.

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.

The Company also announced that its EUA-authorized Linea COVID-19 Assay Kit likely exhibits a unique double S-gene target failure specific to the Omicron variant.
The Linea COVID-19 Assay Kit is a real-time RT-PCR test intended for the qualitative detection of nucleic acid from SARS-CoV-2 in respiratory specimens.
The test is also intended for use with anterior nasal swab specimens that are self-collected in the presence of a healthcare professional from individuals without symptoms.
Related: Applied DNA Stock Jumps On New COVID-19 Testing Contract.
Price Action: APDN shares are up 53.60% at $8.14 during the premarket session on the last check Monday.

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.